Equities

Nuo Therapeutics Inc

AURX:QBB

Nuo Therapeutics Inc

Actions
  • Price (USD)0.55
  • Today's Change0.00 / 0.00%
  • Shares traded6.00k
  • 1 Year change-23.08%
  • Beta1.1310
Data delayed at least 15 minutes, as of Sep 19 2024 19:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.

  • Revenue in USD (TTM)1.03m
  • Net income in USD-2.69m
  • Incorporated1998
  • Employees--
  • Location
    Nuo Therapeutics Inc8285 EL RIO, SUITE 150HOUSTON 77054United StatesUSA
  • Phone+1 (832) 236-9060
  • Fax+1 (240) 499-2690
  • Websitehttps://www.nuot.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
RenovoRx Inc0.00-8.11m23.60m8.00--2.54-----0.6059-0.60590.000.38680.00----0.00-88.58---106.00--------------0.00-------3.47------
Biora Therapeutics Inc860.00k-86.81m23.70m58.00------27.56-5.57-5.560.024-2.490.0253--1.0514,827.59-255.56-122.84---369.01-----10,094.19-415.10---------98.69-87.44-154.63---53.68--
Bolt Biotherapeutics Inc11.17m-66.17m24.11m100.00--0.2809--2.16-1.74-1.740.29382.240.0709----111,660.00-42.03-48.32-47.37-54.03-----592.57-2,267.00----0.00--37.48--21.45---6.61--
Unity Biotechnology Inc0.00-27.86m24.26m19.00--1.23-----1.80-1.800.001.170.00----0.00-36.05-47.21-45.11-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Cognition Therapeutics Inc0.00-31.08m24.46m25.00--1.06-----0.9317-0.93170.000.57360.00----0.00-79.36---104.49-------------263.290.00-------20.52------
Iterum Therapeutics PLC0.00-28.34m24.75m14.00---------2.00-2.000.00-0.6580.00----0.00-86.93-118.12-150.76-199.23-------890,554.10----2.06------13.64---32.09--
Promis Neurosciences Inc0.00-12.20m24.76m6.00---------0.6924-0.69240.00-0.12010.00----0.00-839.15-144.28---262.23-------2,271,047.00------------26.85------
Nuo Therapeutics Inc1.03m-2.69m25.01m----41.78--24.31-0.0622-0.06220.02370.01320.73320.9544.06---191.94-116.16-381.40-354.8479.4870.02-261.78-854.531.39-2,383.080.00--442.12-14.990.0095------
Lisata Therapeutics Inc0.00-21.07m25.13m25.00--0.657-----2.56-2.560.004.600.00----0.00-40.16-45.97-43.61-50.47------------0.00------61.57------
SAB Biotherapeutics Inc2.78m-40.32m25.29m57.00--0.5483--9.10-5.69-5.690.36465.000.0571--9.4448,773.51-82.85---102.37-------1,450.32------0.0817---90.63---125.14------
Lipocine Inc4.80m-8.49m25.51m17.00--1.20--5.31-1.60-1.600.90123.970.1794--109.27282,407.70-31.72-39.32-34.05-45.87-----176.80-442.26----0.00---670.16---51.99------
Surrozen Inc0.00-53.45m26.13m42.00--4.31-----21.74-21.740.001.890.00----0.00-98.01---110.62-------------2.050.00---100.00---19.55------
Marker Therapeutics Inc3.73m-10.31m26.14m8.00--2.69--7.01-1.16-1.170.41961.090.2217--1.76465,930.00-61.30-53.74-71.74-62.25-----276.53-1,438.71----0.00---5.7674.2728.97------
Neurosense Therapeutics Ltd0.00-11.88m26.29m16.00---------0.7299-0.72990.00-0.44880.00----0.00-350.36---5,244.59----------------------18.10------
IGC Pharma Inc1.06m-13.30m26.37m67.00--3.35--24.83-0.2104-0.21040.01670.10420.08090.20288.4015,850.75-101.29-42.46-122.91-46.0760.3620.95-1,252.64-730.001.16--0.0173--47.64-23.45-12.98--53.72--
Aeon Biopharma Inc0.00-305.52m26.44m5.00---------8.40-8.400.00-0.71440.00----0.00-6,646.10----------------9.21---------631.85------
Data as of Sep 19 2024. Currency figures normalised to Nuo Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

4.81%Per cent of shares held by top holders
HolderShares% Held
Deerfield Management Co. LPas of 15 Mar 20242.18m4.80%
Ancora Family Wealth Advisors LLCas of 30 Jun 20244.70k0.01%
Data from 15 May 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.